Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

Abstract excerpt

Many women with hormone receptor-positive breast cancer will receive tamoxifen at some point in their treatment course. Tamoxifen is biotransformed to the potent antiestrogen endoxifen almost exclusively through the cytochrome P450 (CYP) 2D6 isoform. Although prospective data are lacking, the balance of evidence available currently suggests that a single nucleotide polymorphism in the CYP2D6 gene, particularly...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents, Hormonal
• Biotransformation
• Cytochrome P-450 CYP2D6
• Patient Selection
• Pharmacogenetics